Mark Reid

Founder & Managing Director at Graythan Regulatory

Speaker

Mark Reid, BSc (Hons), MMedSc (Drug Development), MBA (Exec), GAICD, RAC is the Founder and Managing Director of Graythan Regulatory Services and also has the role of Director, APAC at Basking Biosciences, supporting the company's clinical, regulatory and partnership pathways across APAC. He has more than 26 years of experience in drug development, regulatory affairs across FDA, EMA, TGA, MHRA and HSA jurisdictions, with particular depth in orphan drug, priority review, cell and gene therapy, and immuno-oncology programmes. As Founder and former CEO/Managing Director of Amivas Inc., he led the 2020 FDA approval of Artesunate for Injection, the only FDA-approved treatment for severe malaria in the United States, and its rollout across 34 countries. Mark has 10 peer-reviewed publications cited across 10 policy and clinical guideline domains including ATAGI, US CDC, US FDA, NASEM, and WHO SAGE. He holds a patent for novel celgosivir dosing regimens for dengue, and has five RAC credentials (Canada, Drugs, EU, General Scope and US).